학술논문
Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
Document Type
Article
Author
Lewis, Alexander C.; Pope, Victoria S.; Tea, Melinda N.; Li, Manjun; Nwosu, Gus O.; Nguyen, Thao M.; Wallington-Beddoe, Craig T.; Moretti, Paul A.B.; Anderson, Dovile; Creek, Darren J.; Costabile, Maurizio; Ali, Saira R.; Thompson-Peach, Chloe A.L.; Dredge, B. Kate; Bert, Andrew G.; Goodall, Gregory J.; Ekert, Paul G.; Brown, Anna L.; D'Andrea, Richard; Robinson, Nirmal; Pitman, Melissa R.; Thomas, Daniel; Ross, David M.; Gliddon, Briony L.; Powell, Jason A.; Pitson, Stuart M.
Source
Blood; 20240101, Issue: Preprints
Subject
Language
ISSN
00064971; 15280020
Abstract
Inducing cell death by the sphingolipid ceramide is a potential anti-cancer strategy, but the underlying mechanisms remain poorly defined. Here, we show that triggering accumulation of ceramide in acute myeloid leukaemia (AML) cells by inhibition of sphingosine kinase induces an apoptotic integrated stress response (ISR) through protein kinase R-mediated activation of the master transcription factor ATF4. This leads to transcription of the BH3-only protein, Noxa, and degradation of the pro-survival Mcl-1 protein on which AML cells are highly dependent on for survival. Targeting this novel ISR pathway in combination with the Bcl-2 inhibitor venetoclax synergistically killed primary AML blasts, including those with venetoclax-resistant mutations, as well as immunophenotypic leukemic stem cells, and reduced leukemic engraftment in patient-derived AML xenografts. Collectively, these findings provide mechanistic insight into the anti-cancer effects of ceramide and pre-clinical evidence for new approaches to augment Bcl-2 inhibition in the therapy of AML and other cancers with high Mcl-1 dependency.